Summit Therapeutics, Inc.

As of October 3, 2025, Summit Therapeutics, Inc. shows a mildly bullish trend based on daily moving averages, despite mixed signals from weekly and monthly indicators, and has outperformed the S&P 500 over the past week and year-to-date.

As of October 3, 2025, Summit Therapeutics, Inc. shows a cautious bullish outlook with mixed technical signals, having outperformed the S&P 500 over the past week but underperformed over the past month, while year-to-date returns stand at 20.09% compared to the S&P 500's 14.18%.

As of September 19, 2025, Summit Therapeutics, Inc. shows a neutral technical trend with mixed indicators, underperforming the S&P 500 in the past month and year, but significantly outperforming it over the 3- and 5-year periods.

As of September 19, 2025, Summit Therapeutics, Inc. shows a neutral technical trend with mixed signals, underperforming the S&P 500 in the short term but significantly outperforming over the past 3 and 5 years.

As of August 27, 2025, Summit Therapeutics, Inc. shows a mildly bullish trend with mixed signals from technical indicators, having outperformed the S&P 500 over the past week but underperformed over the past month and year.

As of November 9, 2022, Summit Therapeutics, Inc. is overvalued with a valuation grade of "does not qualify," reflecting significant financial deterioration, highlighted by a Price to Book Value ratio of 44.41, an EV to EBIT of -63.40, and a concerning -65.56% Return on Equity, despite a strong stock performance of 157.12% over the past year compared to the S&P 500's 10.26%.

As of May 30, 2025, the trend is mildly bullish, supported by daily moving averages and monthly indicators, despite mixed signals from weekly metrics suggesting some bearishness.

As of March 2022, the management team of Summit Therapeutics, Inc. includes Dr. Elaine Stracker as Executive Director and Mr. Rainer Erdtmann as Non-Executive Independent Director.

Summit Therapeutics, Inc. develops treatments for infectious diseases in the Pharmaceuticals & Biotechnology sector. It has a market cap of approximately $14.74 billion and reported a net profit loss of $63 million as of March 2025.

As of Jun 18, Summit Therapeutics, Inc. has a market capitalization of 14,741.92 million, classifying it as a Small Cap company, with net sales of 0.00 million and a net profit of -240.75 million for the latest four quarters. As of December 2024, shareholder's funds were 388.75 million and total assets were 435.56 million.